breast cancer

Switzerland-based Novartis has announced encouraging results from a pivotal Phase III trial demonstrating the efficacy of Afinitor (everolimus) tablets in significantly delaying tumour growth in HER2-positive advanced breast cancer.

The study met the primary endpoint of progression-free survival (PFS) by demonstrating 22% reduction in the risk of disease progression with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients.

Emory University School of Medicine department of haematology and medical oncology educational affairs professor and vice-chair and lead study author Ruth O’Regan said the data demonstrates everolimus’ impact in heavily pretreated HER2 positive advanced breast cancer patients.

"Everolimus works differently than available treatment options for HER2 positive advanced breast cancer by inhibiting mTOR, and may offer an important new option for physicians and their patients," O’Regan said.

Median time to progression in the everolimus combination arm of the breast cancer trials of oral everolimus-3 (BOLERO-3) study was 7.0 months compared to 5.8 months in the placebo combination arm.

About 27% of patient population was pretreated with a lapatinib-containing regimen, while all the subjects showed resistance to trastuzumab-containing regimens.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The overall survival findings, the trial’s main secondary endpoint, have not been matured yet, however no new adverse events were noted in the trial.

Neutropenia, stomatitis, anaemia, leukopenia, fatigue, pyrexia, diarrhoea, nausea, decreased appetite and constipation are the most common all-grade adverse reactions, while the most common Grade 3-4 adverse reactions included neutropenia, leukopenia, anaemia, stomatitis, fatigue, febrile neutropenia, diarrhoea, pyrexia, nausea, hyperglycemia and thrombocytopenia.

Novartis Oncology, oncology development and medical affairs global head Alessandro Riva said; "Our previous advanced breast cancer studies have proven that everolimus plays a key role in treating women with hormone-receptor positive, HER2 negative advanced breast cancer, and now we know it may have a substantial impact in HER2 positive advanced breast cancer."


Image: Excised human breast tissue, showing a stellate area of cancer 2cm in diameter. Photo: John Hayman.